Phase 2 Study of Bortezomib (Velcade) for the Treatment of Steroid Refractory Chronic Graft-vs-Host Disease.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Bortezomib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 15 Jan 2016 Planned End Date changed from 1 Aug 2015 to 1 Jan 2017, according to ClinicalTrials.gov record.
- 15 Jan 2016 Planned primary completion date changed from 1 Aug 2015 to 1 May 2013, according to ClinicalTrials.gov record.
- 16 Mar 2015 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov record.